Henrik Zetterberg

Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease.

Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis.

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

Synaptic retrogenesis and amyloid-beta in Alzheimer's disease.

The szilard hypothesis on the nature of aging revisited.

[Biomarkers in cerebrospinal fluid and blood in memory complaints].

Future screening for incipient Alzheimer's disease--the influence of prevalence on test performance.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Sustained release of neuron-specific enolase to serum in amateur boxers.

Amyloid beta and APP as biomarkers for Alzheimer's disease.

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Subcortical vascular dementia biomarker pattern in mild cognitive impairment.

CSF biomarkers: pinpointing Alzheimer pathogenesis.

Kinesin light chain 1 gene haplotypes in three conformational diseases.

Converging molecular pathways in human neural development and degeneration.

Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract.

Is there a CSF biomarker profile related to depression in elderly women?

Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease.

Biochemical markers in Alzheimer's disease clinical trials.

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?

Study bridges the gap between advanced mass spectrometry and immuno-based multiplex assays.

Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid.

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.

To know or not to know: ethical issues related to early diagnosis of Alzheimer's disease.

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease.

Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.

Cerebrospinal fluid analysis should be considered in patients with cognitive problems.

Biomarker-based dissection of neurodegenerative diseases.

Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method.

Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.

Biomarkers for microglial activation in Alzheimer's disease.

Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid β levels in humans.

CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma.

An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid.

CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease.

Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?

Peptidome analysis of cerebrospinal fluid by LC-MALDI MS.

Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study.

Fluid biomarkers in Alzheimer disease.

Serum levels of LIGHT in MS.

The neuropathology and neurobiology of traumatic brain injury.

Superoxide dismutase gene polymorphisms in patients with age-related cataract.

Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.

Genetic variation of superoxide dismutases in patients with primary open-angle glaucoma.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease.

Cerebrospinal fluid biomarkers in cardiac arrest survivors.

Increased CSF levels of phosphorylated neurofilament heavy protein following bout in amateur boxers.

Automated cerebrospinal fluid cell count--new reference ranges and evaluation of its clinical use in central nervous system infections.

Cerebrospinal fluid α-synuclein levels in Parkinson's disease--changed or unchanged?

Acute sleep deprivation increases serum levels of neuron-specific enolase (NSE) and S100 calcium binding protein B (S-100B) in healthy young men.

EPHA2 Polymorphisms in Estonian Patients with Age-Related Cataract.

Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study.

The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?

CSF Aβ42 predicts early-onset dementia in Parkinson disease.

Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample.

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.

Tau, s-100 calcium-binding protein B, and neuron-specific enolase as biomarkers of concussion-reply.

Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.

An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy.

Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease - a multicenter study.

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Rarity of the Alzheimer disease-protective APP A673T variant in the United States.

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.

Comment on "An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice".

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.

Human cerebrospinal fluid increases the excitability of pyramidal neurons in the in vitro brain slice.

Cerebrospinal fluid total prion protein: a potential in vivo marker of cerebral prion pathology.

Laboratory testing for lyme neuroborreliosis.

Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry.

The distribution of apolipoprotein E genotype over the adult lifespan and in relation to country of birth.

A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals.

Explorative and targeted neuroproteomics in Alzheimer's disease.

Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players.

Estrogen-related Polymorphisms in Estonian Patients with Age-related Cataract.

Repetitive concussions--How dangerous are they?

Fluid markers of traumatic brain injury.

Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease.

Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.

A 9-year prospective population-based study on the association between the APOE*E4 allele and late-life depression in Sweden.

Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus.

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.

Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding.

Monocyte and microglial activation in patients with mood-stabilized bipolar disorder.

Neurological consequences of traumatic brain injuries in sports.

First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study.

A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid.

Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 Carriers.

Amyloid biomarkers in Alzheimer's disease.

Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.

Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.

APP metabolism regulates tau proteostasis in human cerebral cortex neurons.

Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients with bipolar disorder and healthy controls.

Serum visinin-like protein-1 in concussed professional ice hockey players.

First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression.

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection.

Increased levels of inflammatory immune mediators in vitreous from pseudophakic eyes.

CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment.

Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.

C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study.

The impact of Tween 20 on repeatability of amyloid β and tau measurements in cerebrospinal fluid.

Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls.

Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability.

Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments.

The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up.

The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease.

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

Clearance systems in the brain-implications for Alzheimer disease.

Round robin test on quantification of amyloid-β 1-42 in cerebrospinal fluid by mass spectrometry.

Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies.

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Plasma amyloid β-quo vadis?

The relationship between CSF tau markers, hippocampal volume and delayed primacy performance in cognitively intact elderly individuals.

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.

Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction.

Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio.

Protective properties of lysozyme on β-amyloid pathology: implications for Alzheimer disease.

Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.

A Practical Guide to Immunoassay Method Validation.

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.

Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study.

Neurogranin Levels in Cerebrospinal Fluid: A New Addition to the Alzheimer Disease Diagnostic Toolbox.

Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.

Biomarkers in Sporadic and Familial Alzheimer's Disease.

Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition.

Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.

Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?

Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.

Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease.

Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis.

Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.

The Expression of Transthyretin and Amyloid-β Protein Precursor is Altered in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients.

Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease.

The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events.

Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements.

Increased CSF biomarkers of angiogenesis in Parkinson disease.

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.

The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases.

CACNA1C polymorphism and altered phosphorylation of tau in bipolar disorder.

Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease.

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid.

Serum IGF-1 is higher in patients with idiopathic normal pressure hydrocephalus than in the population.

Apolipoprotein E ϵ4 is positively related to spatial performance but unrelated to hippocampal volume in healthy young adults.

Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition.

Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.

Neuromodulation of fast-spiking and non-fast-spiking hippocampal CA1 interneurons by human cerebrospinal fluid.

Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases.

Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair.

Cerebrospinal fluid markers of central nervous system injury in decompression illness - a case-controlled pilot study.

APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment.

Intracranial Arterial 4D-Flow is Associated with Metrics of Brain Health and Alzheimer's Disease.

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.

Serum Neurofilament Light in American Football Athletes over the Course of a Season.

Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease.

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.

Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.

Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football.

Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.

Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids.

Increased CSF neurogranin concentration is specific to Alzheimer disease.

Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes.

Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.

Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET.

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study.

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.

Erratum to: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.

Serum erythropoietin and outcome after ischaemic stroke: a prospective study.

Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry.

α-Synuclein in Neurodegeneration-A Good Protein that may go Bad.

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.

YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis.

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects.

Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation.

Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.

The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview.

Identification of tissue-specific cell death using methylation patterns of circulating DNA.

Defeating Alzheimer's disease and other dementias: a priority for European science and society.

β-Amyloid precursor protein-b is essential for Mauthner cell development in the zebrafish in a Notch-dependent manner.

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges.

Clearance systems in the brain--implications for Alzheimer diseaser.

C3 deficiency ameliorates the negative effects of irradiation of the young brain on hippocampal development and learning.

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.

Plasma neurofilament light chain predicts progression in progressive supranuclear palsy.

Putamen volume and its clinical and neurological correlates in primary HIV infection.

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.

Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.

Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.

Cerebrospinal fluid levels of insulin, leptin, and agouti-related protein in relation to BMI in pregnant women.

Monitoring of 30 marker candidates in early Parkinson disease as progression markers.

Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.

CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation.

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study.

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia.

Plasma β-amyloid in Alzheimer's disease and vascular disease.

Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment.

Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.

Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke.

APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.

Corrigendum to: "Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study" [EBioMedicine 3 (216) 135-140].

Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.

Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation.

Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration.

Blood biomarkers indicate mild neuroaxonal injury and increased amyloid β production after transient hypoxia during breath-hold diving.

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease.

Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients.

No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).

Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection.

The APOE Genotype in Idiopathic Normal Pressure Hydrocephalus.

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders.

Validation of a new assay for α-synuclein detection in cerebrospinal fluid.

Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease.

State-dependent alterations in cerebrospinal fluid Aβ42 levels in cognitively intact elderly with late-life major depression.

Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.

Calcium supplementation and risk of dementia in women with cerebrovascular disease.

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS.

Serum neurofilament light protein as a marker for diffuse axonal injury - results from a case series study.

Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster.

Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?

Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid Aβ42 Levels in Cognitively Normal Elderly.

Reference measurement procedure for CSF amyloid beta (Aβ)1-42 and the CSF Aβ1-42 /Aβ1-40 ratio - a cross-validation study against amyloid PET.

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia.

Specific Triazine Herbicides Induce Amyloid-β42 Production.

Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.

CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease.

No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF.

Fluid biomarkers for mild traumatic brain injury and related conditions.

Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.

The ACE Gene Is Associated with Late-Life Major Depression and Age at Dementia Onset in a Population-Based Cohort.

Cerebrospinal fluid viral load and biomarkers of neuronal and glial cells in Ramsay Hunt syndrome.

Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease.

Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders.

Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury.

Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease.

Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease.

Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization.

Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium.

Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies.

Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: a Longitudinal Study.

Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration.

Plasma concentrations of free amyloid-β cannot predict the development of Alzheimer's disease.

A common challenge in older adults: Classification, overlap, and therapy of depression and dementia.

Plasma tau in Alzheimer disease.

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease.

Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.

Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress.

CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults.

Serum neurofilament light protein predicts clinical outcome in traumatic brain injury.

Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease.

Expanding the cerebrospinal fluid endopeptidome.

Genome-wide association study identifies MAPT locus influencing human plasma tau levels.

Neurofilament Protein and Antineurofilament Antibodies Following Traumatic Brain Injury-Reply.

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.

Ex vivo (18)O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway.

The immune response of the human brain to abdominal surgery.

Astroglial activation and altered amyloid metabolism in human repetitive concussion.

Microstructural white matter alterations in preclinical Alzheimer's disease detected using free water elimination diffusion tensor imaging.

Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports.

Applying fluid biomarkers to Alzheimer's disease.

Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition.

A Season of American Football Is Not Associated with Changes in Plasma Tau.

Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study.

Neuroinflammation and Tau Interact with Amyloid in Predicting Sleep Problems in Aging Independently of Atrophy.

Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls.

Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.

Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity.

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders.

Serum tau and neurological outcome in cardiac arrest.

A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.

Structural brain abnormalities in successfully treated HIV infection: associations with disease and cerebrospinal fluid biomarkers.

Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice.

Low-dose γ-secretase inhibition increases secretion of Aβ peptides and intracellular oligomeric Aβ.

Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly: A Longitudinal Study.

Central and Peripheral Leptin and Agouti-Related Protein during and after Pregnancy in Relation to Weight Change.